Market Newsdesk

TAMPA, Fla., Nov. 11, 2020 /PRNewswire/ – Primo Water Corporation (NYSE: PRMW) (TSX: PRMW) (the “Company” or “Primo”), a leading provider of water direct to consumers and water filtration services in North America and Europe as well as a leading provider of water dispensers, spring and purified bottled water, and self-service refill drinking water in the U.S. and Canada, today announced that the International Bottled Water Association (IBWA) has awarded Primo Water North America employees Tom Condon, Director of Technical Services, with the IBWA/Kristin Safran Directors’ Award, Jon Cleaver, Route Sales Representative, with the Route Salesperson of the Year Award, and Monika Morgan, Plant Manager, with the Plant Manager of the Year Award at the association’s virtual 2020 IBWA Annual Business Conference and Trade Show on November 9, 2020.

Created in 2006, the IBWA Directors’ Award recognizes members whose advocacy, commitment, and actions on behalf of IBWA—and the bottled water industry—have achieved clear and measurable results for both IBWA and the bottled water industry as a whole. Tom Condon is responsible for the design and troubleshooting of water processing equipment, spring water source evaluations, and technical improvement of processes and controls at Primo Water North America. Tom has also served on and contributed to several other IBWA committees and sub-committees, including the Virus/Microbial Subcommittee, Packaging Subcommittee, Audit Program Evaluation Team, Gray Areas Task Force, and Pilot Plant Task Force, among many others. He was instrumental in assisting the association in addressing complex technical and regulatory issues.

“We feel incredibly fortunate to benefit from the depth of knowledge from team members like Tom,” said Dave Muscato, President of Primo Water North America. “With more than 40 years of experience in the bottled water industry, Tom has brought his expertise to every aspect of our processes and controls to ensure that our spring water is sourced in a sustainable manner and that our customers receive the highest quality water solutions and products. I can’t think of a more deserving individual for this award.”

When it comes to customer service in the bottled water industry, nobody exemplifies it better than route salespeople. They are truly on the front lines every day serving our customers – which is why the IBWA recognizes outstanding performance in this critical industry category. The determination of the award is based on performance in multiple areas, including revenue, volume, serve rate, stops per day, customers per route and penetration, among other categories. Jon Cleaver offers and sells the Company’s full portfolio of products and consistently looks for opportunities to increase revenue on his route. A top performer in all sales initiatives, Jon is very proactive and strives to anticipate customers’ needs.

Muscato commented, “Jon has a great rapport with his customers, managers and peers. With his calm demeanor, courtesy and professionalism, he is quick to participate in huddle discussions and share the knowledge he has accumulated as a 13-year Alhambra veteran. Jon treats his route as if it were his personally-owned small company, taking full accountability for all aspects of the business. He is a vocal leader, promoter of a strong safety culture, and an invaluable asset in the Sacramento branch.”

The IBWA Plant Manager of the Year Award recognizes the hard work and dedication that plant managers exemplify for their companies and the bottled water industry. A plant manager makes a tremendous impact in achieving business goals and objectives. Monika Morgan manages both the Kent, Washington and Portland, Oregon plants and she has helped the Kent plant win the IBWA Excellence in Manufacturing Award for 12 consecutive years. In 2019, Kent was named in the top three large plants for quality and earned the best internal audit score for large plants, with 100% completion of follow-ups. Kent more than doubled on-time shipments in 2019 and rose to 95% in 2020.

Muscato added, “Monika is an exemplary member of our team and has become an influential and innovative leader at Primo Water North America. Since joining the Company as a production operator, Monika has held roles of increasing responsibility in production and quality during her 22 years with us and continues to demonstrate her commitment to Primo and our customers. It’s the plant manager who ensures, on a daily basis, that our bottled water is a safe product for our customers. Her significant experience, varied background and track record of driving results make her one of the most effective facility leaders in our organization.”

ABOUT PRIMO WATER NORTH AMERICA

Primo Water North America, a wholly-owned subsidiary of Primo Water Corporation, is a U.S.-based company providing bottled water, break room supplies, and equipment and services for water filtration systems. They provide products to over a million homes, offices, restaurants, food service organizations, convenience stores, and retail locations across the country. Among its best-known bottled water brands are Alhambra^®, Crystal Rock^®, Crystal Springs^®, Deep Rock^®,  Hinckley Springs^®,  Kentwood Springs^®, Mount Olympus^®, Nursery_® Water, Sierra Springs^®, Sparkletts^®. Learn more at https://www.water.com/.

ABOUT PRIMO WATER CORPORATION

Primo Water Corporation is a leading pure-play water solutions provider in North America, Europe and Israel and generates approximately $2.1 billion in annual revenue. Primo operates largely under a recurring razor/razorblade revenue model. The razor in Primo’s revenue model is its industry leading line-up of sleek and innovative water dispensers, which are sold through major retailers and online at various price points or leased to customers. The dispensers help increase household penetration which drives recurring purchases of Primo’s razorblade offering. Primo’s razorblade offering is comprised of Water Direct, Water Exchange, and Water Refill. Through its Water Direct business, Primo delivers sustainable hydration solutions across its 21-country footprint direct to the customer’s door, whether at home or to commercial businesses. Through its Water Exchange and Water Refill businesses, Primo offers pre-filled and reusable containers at over 13,000 locations and water refill units at approximately 22,000 locations, respectively. Primo also offers water filtration units across its 21-country footprint representing a top five position.

Primo’s water solutions expand consumer access to purified, spring and mineral water to promote a healthier, more sustainable lifestyle while simultaneously reducing plastic waste and pollution. Primo is committed to its water stewardship standards and is proud to partner with the International Bottled Water Association (IBWA) in North America as well as with Watercoolers Europe (WE), which ensure strict adherence to safety, quality, sanitation and regulatory standards for the benefit of consumer protection.

Primo is headquartered in Tampa, Florida (USA). For more information, visit www.primowatercorp.com.

ABOUT THE INTERNATIONAL BOTTLED WATER ASSOCIATION (IBWA)

The International Bottled Water Association (IBWA) is the authoritative source of information about all types of bottled waters, including spring, mineral, purified, artesian, and sparkling. Founded in 1958, IBWA’s membership includes U.S. and international bottlers, distributors and suppliers. IBWA is committed to working with the U.S. Food and Drug Administration (FDA), which regulates bottled water as a packaged food product, to set comprehensive and stringent standards for safe, high-quality bottled water products.

In addition to FDA regulations, IBWA member bottlers must adhere to the IBWA Bottled Water Code of Practice, which mandates additional standards and practices that in some cases are more stringent than federal and state regulations. A key feature of the IBWA Bottled Water Code of Practice is a mandatory annual plant inspection by an independent, third-party organization.

View original content to download multimedia:http://www.prnewswire.com/news-releases/primo-water-north-america-proudly-recognizes-its-international-bottled-water-association-award-winners-for-2020-301171342.html

SOURCE Primo Water Corporation

DES MOINES, Iowa, Nov. 11, 2020 /PRNewswire/ — The Meredith Corporation (NYSE:MDP) Board of Directors announced several actions following its Annual Shareholders Meeting today:

Thomas H. Harty Elected Chairman and Elizabeth E. Tallett Elected Lead Independent Director

Harty, a member of Meredith Corporation’s Board of Directors since 2017, will also retain his post as President and Chief Executive Officer. Harty joined Meredith in 2004 as Vice President of its Magazine Group and was named National Media Group President in 2010. He became President and Chief Operating Officer of Meredith Corp. in 2016 and its Chief Executive Officer in 2018. Harty succeeds Stephen M. Lacy, who is retiring from Meredith’s Board after 16 years of service as a Director.

“On behalf of the Board of Directors and the Meredith family, I would like to thank Steve for the 22 years of relentless passion, dedication and commitment to excellence he delivered in service of Meredith Corporation,” said Vice Chairman Mell Meredith Frazier.

Tallett has been a member of the Meredith Board since 2008. In her new role, she will collaborate with Chairman Harty and Vice Chairman Frazier on setting agendas for Board meetings, including executive sessions; facilitate discussion among the independent directors on key issues outside of Board meetings; and provide advice and counsel to the Board as requested.

“Liz brings broad board and independent director experience to Meredith, supported by a career focused on operational and strategic leadership roles at large and complex organizations in the consumer products and biopharmaceutical industries,” said Harty. “We look forward to working together with Liz in her expanded board role at Meredith.”

Tallett currently serves as Chair of Anthem Inc. and is a member of the boards at Moderna Inc., Qiagen Inc., and Principal Financial Group. She was Lead Independent Director at Principal until this year, and previously served in that role at Coventry Health Care Inc. Tallett’s previously held senior management positions include principal of Hunter Partners, President and Chief Executive Officer of Transcell Technologies Inc., President of Centocor Pharmaceuticals, and she was a member of the Executive Committee of Parke-Davis. Tallett earned a dual first-class honors degree in mathematics and economics from Nottingham University.

Elizabeth E. Tallett, Donald C. Berg and Gregory Coleman Elected to New Board Terms

Tallett was elected to serve as a Class III Director with a term expiring in 2022. Berg and Coleman were elected to serve as Class I Directors with terms expiring in 2023.

Beth J. Kaplan Elected Chairman of Meredith’s Human Resource and Compensation Committee

Kaplan joins Mell Meredith Frasier (Nominating/Governance) and Donald C. Berg (Audit) as Meredith Board Committee chairs.

Four Shareholder Proposals Approved

Meredith shareholders approved four proposals, all of which were supported by the Board. These were:

• Approval of Advisory Resolution on Executive Compensation Discussion & Analysis
• Amendment & Restatement to Meredith Corporation Employee Stock Purchase Plan
• Ratification of Appointment of Independent Registered Public Accounting Firm
• Amendment to Restated Articles of Incorporation

ABOUT MEREDITH CORPORATION

Meredith Corporation (MDP: NYSE), a leading media company for nearly 120 years, produces service journalism that engages audiences with essential, inspiring and trusted content. We reach consumers where they are across multiple platforms including digital, video, print, and broadcast television. Meredith’s National Media Group reaches nearly 95 percent of all U.S. women and more than 190 million unduplicated American consumers every month through such iconic brands as PEOPLE, Better Homes & Gardens, Allrecipes, Southern Living, and REAL SIMPLE. Meredith’s premium digital network reaches more than 150 million consumers each month. The company is the No. 1 U.S. magazine operator with 36 million subscribers, and the No. 2 global licensor with robust brand licensing activities that include a Better Homes & Gardens partnership with Walmart. Meredith’s Local Media Group portfolio includes 17 television stations reaching 11 percent of U.S. households and 30 million viewers. Meredith’s portfolio is concentrated in large, fast-growing markets, with seven stations in the nation’s Top 25 markets, including Atlanta, Phoenix, St. Louis and Portland, and 13 stations in the Top 50.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/meredith-corporation-board-of-directors-elects-thomas-harty-chairman-and-elizabeth-tallett-lead-independent-director-301171324.html

SOURCE Meredith Corporation

SAN FRANCISCO, Nov. 11, 2020 /PRNewswire/ — Skillz Inc. (“Skillz”), the leading mobile games platform connecting players in fair, fun, and meaningful competition, today announced that its CEO and founder, Andrew Paradise, will participate at J.P. Morgan’s virtual Global Technology, Media, and Telecom in Asia Conference being held November 16-18, 2020.

Paradise will be participating in a panel titled “How Esports are Reshaping the Gaming Landscape in Asia and Globally” on November 16, 2020, at 10:15am HKT / November 15, 2020, at 6:15pm PST.

Access to a live audio webcast of the discussion in listen-only mode will be available through the “Investors” section of the Skillz website at www.skillz.com. A replay of the webcast will be archived on the company’s website.

About Skillz Inc.

Skillz
 is the leading mobile games platform that connects players in fair, fun, and meaningful competition. The Skillz platform helps developers build multi-million dollar franchises by enabling social competition in their games. Leveraging its patented technology, Skillz hosts billions of casual esports tournaments for millions of mobile players worldwide, and distributes millions in prizes each month. Skillz has earned recognition as one of Fast Company’s Most Innovative Companies, CNBC’s Disruptor 50, Forbes’ Next Billion-Dollar Startups, and the #1 fastest-growing company in America on the Inc. 5000. On September 2, 2020, Skillz entered into a business combination agreement with Flying Eagle Acquisition Corp. (NYSE: FEAC, FEAC.U and FEAC WS). Upon the closing of the transaction, the combined company intends to change its name to Skillz and trade on the NYSE under the ticker symbol “SKLZ.” www.skillz.com 

Contacts
For Skillz PR: [email protected]
For Skillz IR: [email protected] 

Source: Skillz Inc.

View original content:http://www.prnewswire.com/news-releases/skillz-to-participate-in-jp-morgans-global-technology-media-and-telecom-in-asia-virtual-conference-301171264.html

SOURCE Skillz Inc.

DENVER, Nov. 11, 2020 /PRNewswire/ — RiverNorth Opportunities Fund, Inc. (NYSE: RIV) (the “Fund”) is pleased to announce the successful completion of its transferable rights offering (the “Offering”) and the final results thereof. The Fund will issue a total of 575,706 new common shares as a result of the Offering, which closed on November 6, 2020 (the “Expiration Date”).

The subscription price of $14.08 per share in the Offering was established on the Expiration Date based upon a formula equal to 95% of the Fund’s reported net asset value per share on the Expiration Date.  Gross proceeds received by the Fund, before any expenses of the Offering, are expected to total approximately $8.1 million.

This press release shall not constitute an offer to sell or constitute a solicitation of an offer to buy. Investors should read the prospectus supplement and accompanying prospectus and consider the investment objective, risks, fees and expenses of the Fund carefully before investing. To obtain a copy of the prospectus supplement and accompanying prospectus or the Fund’s annual report or semi-annual report, each of which contains this and other information about the Fund, visit www.rivernorthcef.com or call 855.830.1222. Please read them carefully before investing.

RiverNorth Opportunities Fund, Inc.

The investment objective of the Fund is total return consisting of capital appreciation and current income. The Fund had approximately $140.3 million of net assets and 9.4 million shares of common stock outstanding as of September 30, 2020.

The Fund is a closed-end fund and does not continuously issue stock for sale as open-end mutual funds do. The Fund is trading in the secondary market. Investors wishing to buy or sell stock need to place orders through an intermediary or broker. The share price of a closed-end fund is based on the market value. ALPS Advisors, Inc. is the investment adviser to the Fund. RiverNorth Capital Management, LLC is the investment sub-adviser to the Fund. RiverNorth is not affiliated with ALPS or any of its affiliates.

About SS&C Technologies

SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices around the world. Some 18,000 financial services and healthcare organizations, from the world’s largest companies to small and mid-market firms, rely on SS&C for expertise, scale and technology. Additional information about SS&C (Nasdaq: SSNC) is available at www.ssctech.com.

About ALPS Advisors

ALPS Advisors, Inc., a wholly-owned subsidiary of SS&C Technologies, Inc., is a leading provider of investment products for advisors and institutions. Headquartered in Denver, CO with over $12.14 billion under management as of September 30, 2020, ALPS Advisors is an open architecture boutique investment manager offering portfolio building blocks, active insight and an unwavering drive to guide clients to investment outcomes across sustainable income, thematic and alternative growth strategies. For more information, visit www.alpsfunds.com/.

RiverNorth Capital Management, LLC

RiverNorth is an investment management firm founded in 2000 that specializes in opportunistic strategies in niche markets where the potential to exploit inefficiencies is greatest. RiverNorth is the manager to multiple registered and private funds.

ALPS Portfolio Solutions Distributor, Inc., FINRA Member.

ALPS Portfolio Solutions Distributor, Inc., ALPS Distributors, Inc. and ALPS Advisors, Inc. are affiliated.

NOT FDIC INSURED | May Lose Value | No Bank Guarantee

View original content:http://www.prnewswire.com/news-releases/rivernorth-opportunities-fund-inc-announces-final-results-of-rights-offering-301171214.html

SOURCE RiverNorth Opportunities Fund, Inc

NEW HAVEN, Conn., Nov. 11, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases including spinocerebellar ataxia, today announced its partnership with the National Ataxia Foundation (NAF) to help the nonprofit organization launch the NAF Drug Development Collaborative. As the first pharmaceutical industry member to commit support, Biohaven’s partnership will help NAF accelerate the development of new treatments for Ataxia.

Melissa Wolfe Beiner, M.D., Director of Research and Development and Clinical Lead for the Ataxia program at Biohaven, commented, “Biohaven is extremely pleased to be the first industry partner to join this important consortium. We are deeply committed to the Ataxia community, as demonstrated by our longstanding partnership with NAF and leading neurologists in the ataxia field from around the world. Together with NAF and our industry peers, we will foster a collaborative environment in which scientists, physicians, and patient advocates can come together to advance novel treatments for people suffering from these debilitating neurodegenerative disorders.”

With its launch officially announced on November 5, the NAF Drug Development Collaborative will assemble members of the pharmaceutical industry around the common goal of accelerating the development of new treatments for Ataxia, a group of progressive neurodegenerative diseases for which no specific treatment or cure is available.  The industry consortium will apply its collective expertise to harness shared opportunities and tackle challenges of drug development through initiatives such as natural history and biosample data collection, development of biomarkers, validation of disease rating scales, refinement of clinical trial design, exploration of patient-reported outcomes and other data critical to the development and approval of safe and effective therapies.

Andrew Rosen, NAF Executive Director, stated, “Biohaven has been a true partner to NAF throughout their therapy development process.  They have been so willing to share insights with us, and in turn, we have done everything we can to provide communications channels to our members and help recruit patients for their clinical trials.  As the first member of the NAF Drug Development Collaborative, Biohaven has once again shown their leadership in the Ataxia space.”

Biohaven is currently enrolling participants in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in Spinocerebellar Ataxia at 21 sites across the United States.  More information about Biohaven’s clinical trial in SCA patients can be found at www.clinicaltrials.gov [NCT03701399] and at https://www.scatrial.org/.   

About Spinocerebellar Ataxia (SCA)

Hereditary Spinocerebellar Ataxias are potentially fatal, rare and severely debilitating neurodegenerative disorders affecting the cerebellum. They are characterized clinically by progressive ataxia symptoms, including difficulties with balance, speech, and coordination, and are attributed to various autosomal dominant genetic mutations. There are currently no FDA-approved treatments and no cure for SCA. 

About Troriluzole

Troriluzole is a new chemical entity that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. Troriluzole is thought to normalize synaptic glutamate levels, which are deregulated in a range of neurological and neuropsychiatric diseases. Troriluzole is believed to increase cycling of glutamate by increasing expression and function of excitatory amino acid transporters (i.e., EAAT2) located on glial cells and 2) decreasing presynaptic glutamate release. More information about troriluzole can be found at the Biohaven’s website www.biohavenpharma.com/science-pipeline/glutamate/troriluzole.

About Biohaven
Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven’s neuroinnovation portfolio includes FDA-approved NURTEC™ ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for spinocerebellar ataxia, obsessive-compulsive disorder and Alzheimer’s disease; and myeloperoxidase (MPO) inhibition for multiple system atrophy and amyotrophic lateral sclerosis. More information about Biohaven is available at www.biohavenpharma.com.

About the National Ataxia Foundation (NAF)

NAF is a nonprofit organization established in 1957 to help persons with Ataxia and their families. The Foundation’s primary purpose is to support Ataxia research, provide vital programs and services for Ataxia families, and help in the search for a cure.  NAF is the only organization in the United States dedicated to the disease that serves all types of Ataxia.  NAF works closely with the world’s leading Ataxia researchers, promoting exchanges of ideas and innovation in Ataxia discovery.

Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe”, “continue”, “may”, “will” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of Biohaven’s management about troriluzole as a possible treatment for Spinocerebellar Ataxia, statements about expected study enrollments and completions, and expected future regulatory filings and approvals. Factors that could affect these forward-looking statements include those related to: Biohaven’s ability to effectively develop troriluzole, complying with applicable U.S. regulatory requirements, the expected timing, commencement and outcomes of Biohaven’s planned and ongoing clinical trials, the timing of planned interactions and filings with the FDA, the timing and outcome of expected regulatory filings, the potential commercialization of Biohaven’s product candidates, the potential for Biohaven’s product candidates to be first in class or best in class therapies and the effectiveness and safety of Biohaven’s product candidates. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. Additional important factors to be considered in connection with forward-looking statements are described in the “Risk Factors” section of Biohaven’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on February 26, 2020, and Biohaven’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the Securities and Exchange Commission on November 9, 2020. The forward-looking statements are made as of this date and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Biohaven Contact

Dr. Vlad Coric
Chief Executive Officer
[email protected]

NURTEC is a trademark of Biohaven Pharmaceutical Ireland DAC.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/biohaven-pharmaceuticals-inaugural-partner-of-national-ataxia-foundations-drug-development-collaborative-301171275.html

SOURCE Biohaven Pharmaceutical Holding Company Ltd.

NEWARK, Calif., Nov. 11, 2020 /PRNewswire/ — Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Virtual 2020 London Healthcare Conference.

Presentation details:
Date: Tuesday, Nov. 17, 2020
Time: 5:35 p.m. GMT (12:35 p.m. EST)

A live and archived webcast of the event will be available at https://wsw.com/webcast/jeff141/ptgx/1873875 and in the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage assets. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn’s disease as the initial indication. In addition to PTG-200, two oral peptide interleukin-23 receptor antagonist candidates from a collaboration with Janssen Biotech, Inc., are in development and have been selected for advancement into clinical studies. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.

Protagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com.

View original content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference-301171288.html

SOURCE Protagonist Therapeutics, Inc.

NOVI, Mich., Nov. 11, 2020 /PRNewswire/ — Stoneridge, Inc. (NYSE: SRI) today announced that Jon DeGaynor, president and chief executive officer, and Bob Krakowiak, chief financial officer, will participate in the Stephens Annual Investment Conference 2020 with a fireside chat at 8:00 a.m. ET on Wednesday, November 18, 2020. Details on how to join the fireside chat via webcast will be posted to the “Investors/Webcasts & Presentations” section of the Company’s website (www.stoneridge.com) prior to the presentation. 

About Stoneridge, Inc.

Stoneridge, Inc., headquartered in Novi, Michigan, is an independent designer and manufacturer of highly engineered electrical and electronic components, modules and systems principally for the automotive, commercial vehicle, motorcycle, agricultural and off-highway vehicle markets. Additional information about Stoneridge can be found at Stoneridge.com. 

Contacts: 

 

View original content:http://www.prnewswire.com/news-releases/stoneridge-to-present-at-stephens-annual-investment-conference-2020-301171238.html

SOURCE Stoneridge, Inc.

XIAMEN, China, Nov. 11, 2020 /PRNewswire/ — Blue Hat Interactive Entertainment Technology (“Blue Hat” or the “Company”) (NASDAQ: BHAT), a leading producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China, today announced  it has received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market, since the closing bid price for the Company’s common shares listed on Nasdaq was below US$1.00 for 30 consecutive trading days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

The notification has no immediate effect on the listing of the Company’s common shares on Nasdaq.

In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until May 5, 2021, to regain compliance with the minimum bid price requirement during which time the Company’s ordinary shares will continue to trade on the Nasdaq Capital Market. If at any time before May 5, 2021 the bid price of the Company’s ordinary shares closes at or above US$1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement. In the event the Company does not regain compliance by May 5, 2021, the Company may be eligible for additional time to regain compliance or may face delisting.

The Company intends to monitor the closing bid price of its ordinary shares between now and May 5, 2021, and intends to cure the deficiency within the prescribed compliance period.

About Blue Hat
Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China, including interactive educational materials, mobile games, and toys with mobile game features. The Company’s interactive entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the Company’s investor relations website at . The Company routinely provides important information on its website.

Forward-Looking Statements 
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the Company’s SEC filings. These risks and uncertainties could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements.

Contacts:
Blue Hat Interactive Entertainment Technology
Phone: +86 (592) 228-0010
Email: [email protected]

Investor Relations:

 

View original content:http://www.prnewswire.com/news-releases/blue-hat-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency-301171113.html

SOURCE Blue Hat Interactive Entertainment Technology